The drug in question - called SB742457 - is a selective serotonin 5-HT6 receptor antagonist and, according to Roivant, has "the potential to improve cognition and function in multiple central ...
Its flagship project was intepirdine, an experimental 5-HT6 receptor antagonist it acquired from GSK, but that failed to show efficacy in a phase 3 trial reported in 2018 and the programme was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback